Cardiac Drug Development Guide

ISBN-13: 9781588290977 / Angielski / Twarda / 2003 / 431 str.

Michael K. Pugsley; Michael K. Pugsley

Opis

Cardiac Drug Development Guide outlines, in detail, the therapeutics of cardiac medicine currently at the cutting edge of scientific research and development around the world. This volume integrates basic and clinical cardiac pharmacology by c- bining, for the first time, both classical and molecular aspects of therapeutic drug development. The chapters comprise a broad spectrum of therapeutic areas and hence involve a comprehensive discussion of molecular, biochemical, and electrophy- ological concepts based on years of in vitro as well as in vivo pharmacological st- ies. In addition, the latter part of the book includes comprehensive clinical cardiac chapters that describe important topics in molecular medicine. These chapters also discuss current clinical therapeutic trends in medicine and provide an evaluation of the efficacy of novel drugs in these areas. Cardiac Drug Development Guide has many distinctive and outstanding features that set it apart from other cardiac pharmacology books. This book introduces topics in an easily understandable format for researchers in many varying disciplines by integrating and thereby simplifying concepts not usually discussed across a broad range of cardiac disciplines and in a highly technical field. Each chapter not only introduces and describes the physiology, pharmacology, and pathophysiology of the disease, but also overviews the clinical implications of drug development, what stages these areas are currently in, and also reviews some of the methodologies involved in drug discovery and development. As a result, this book provides a comprehensive overview of the most advanced procedures in cardiac pharmacology today.

Recenzje

"This book provides a comprehensive overview of many advanced procedures in cardiac pharmacology that should be useful for graduate students and academic scientists as well as researchers in the pharmaceutical and biotechnology drug industries. This is an excellent book for researchers with an interest in cardiac pharmacology. Chapters address a broad spectrum of therapeutic areas and discuss appropriate molecular, biochemical, and electrophysiological in vitro as well as in vivo approaches used in the investigation of cardiovascular pharmacology. Moreover, the book addresses current clinical therapeutic trends in cardiovascular medicine."-Doody's Health Sciences Book Review Journal

"The scope of material covered is comprehensive, providing eclectic coverage of some very topical issues in cardiac biology and cardiac medicine...most of the chapters will be of interest to a much wider audience than pharmacologists...a worthwhile purchase." - Journal of Pharmacological and Toxicological Methods

"This textbook is a comprehensive look into the latest in cardiovascular drug developments and novel therapeutic agents. It covers a broad spectrum of therapeutic areas including ionic channels, adenoviral vector delivery for cardiovascular gene therapy, pharmacometrics, and gender differences in heart failure and angiogenesis therapy in coronary heart disease. It would be useful for clinical researchers and pharmacologists in cardiac drug development. Research scientists, graduate students and pharmacologists involved in both the pharmaceutical and biotechnological drug industries would benefit from this book." - E-STREAMS

Spis treści

I. Introduction Cardiac Drug Development: From Animal Models to Clinical Trials Michael K. Pugsley II . Novel Molecular Targets for Cardiac Drug Development The Role of Cardiac Pacemaker Currents in Antiarrhythmic Drug Discovery David A. Saint Oxygen Free Radicals in Heart Disease: Novel Therapies Elizabeth Roth and Laszlo Hejjel Mitogen-Activated Protein Kinases-Mediated Signaling in Cardiac Pathology: A Perspective of Novel Therapeutic Targets? Tanya Ravingerova, Miroslav Barancik, and Monika Strniskova Development of Anti-Inflammatory Drugs for Cardiovascular Disease Melanie B. Smith and David J. Lefer Development and Use of Platelet Glycoprotein Antagonists in Heart Disease Joel S. Bennett The Sodium-Hydrogen Exchange System in the Heart: A Target for the Protection of the Ischemic and Reperfused Heart and Inhibition of Heart Failure Morris Karmazyn Nitric Oxide and Cardiac Ischemia Mariarosaria Bucci, Inmaculada Posadas Mayo, and Giuseppe Cirino III. Functional Endpoints Evaluating Cardiac Drug Activity Ionic Mechanisms of Atrial Fibrillation J. Christian Hesketh and David Fedida Targeting Ischemic Ventricular Arrhythmias Michael J. A. Walker and Leon J. Guppy Biochemical Mediators of Ventricular Arrhythmias in Ischemic Heart Disease Hugh Clements-Jewery and Michael J. Curtis Heterologous Expression Systems and Screening Technologies in Ion Channel Drug Discovery Maurizio Taglialatela Molecular Diversity of Ion Channels in the Mouse Heart: A Suitable Model for Cardiac Drug Development? Jeanne M. Nerbonne Delayed Protection of the Myocardium: A Novel Therapeutic Window for Cardiac Drug Development László Szekeres and James Parratt IV. Clinical Aspects in Cardiac Drug Development Cardiac TroponinTesting for Detection of Myocardial Infarction: Clinical Utility and Analytical Issues Fred S. Apple A Genetic Basis for Cardiac Arrhythmias: Current Status and the Future Jeffrey A. Towbin, Matteo Vatta, Hua Li, and Neil E. Bowles Myocardial Adenoviral Vector Delivery for Cardiovascular Gene Therapy Hendrik T. Tevaearai, Andrea D. Eckhart, and Walter J. Koch The Role of Pharmacometrics in Cardiovascular Drug Development Paul J. Williams, Amit Desai, and Ene Ette Gender Differences in Heart Failure: Concerns for Drug Development Mark A. Sussman Angiogenesis Therapies for Coronary Artery Disease: Trials and Tribulations Michael Simons Index

Blurb

The revolution in molecular medicine makes it imperative to integrate the classical and molecular approaches to drug development for the treatment of heart disease, the number one killer in North America and Europe. In the Cardiac Drug Development Guide, basic medical researchers, clinicians, and pharmacologists join forces to comprehensively survey the most recent breakthroughs in molecular cardiology and review the latest drug discoveries in cardiac and cardiovascular medicine. Topics range from novel molecular targets for cardiac drug development, to functional endpoints for evaluating cardiac drug activity, to clinical aspects of cardiovascular therapeutics. The authors describe the most advanced procedures in cardiovascular pharmacology, including in vivo and in vitro whole animal studies, the electrophysiological methods used to study pacemaker cells, and the application of biochemical principles and technologies to novel therapeutic agents. Also discussed are the methods used to express the ion channels involved in cardiovascular pharmacology, adenoviral vector delivery for cardiovascular gene therapy, pharmacometrics in cardiovascular drug development, gender differences in heart failure, and angiogenesis therapies for coronary heart disease. Each chapter concisely illustrates the concepts described and includes comprehensive background information, detailed figures and tables, and an up-to-date list of the most important references.
Comprehensive and easy-to-understand, the Cardiac Drug Development Guide offers pharmacologists, cardiologists, and physiologists not only a gold-standard survey of the many different methods being used to develop new heart drugs, but also details powerful new ways in which cardiovascular disease is targeted, from the whole organ to the genetic level.